Recurrent Ovarian Cancer: SOC-1 Trial with Rongyu Zang and Tingyan Shi
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Rongyu Zang and Tingyan Shi to discuss recurrent ovarian cancer and the SOC-1 Trial. Professor Zang is the Director of the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. He has been specializing in gynecologic oncology, especially in clinical and translational research of advanced and recurrent ovarian cancer for the last two decades. As the founder of Shanghai Gynecologic Oncology Group (SGOG), he has been closely associated with the Gynecologic Cancer InterGroup since 2009. Professor Zang initiated several national and international multi-center randomised clinical trials, including the dose-dense EPIC trial and the SUNNY trial for advanced ovarian cancer, as well as the secondary cytoreduction trial for recurrent ovarian cancer, and so on. Dr. Shi is an Associate Professor of Oncology in the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. She has focused on clinical and translational research in gynecologic oncology for over ten years. Dr. Shi has been trained in the Young Investigator Program of Gynecologic Cancer InterGroup, and participated in several international and national multi-center randomized clinical trials for ovarian cancer. Highlights + SOC-1 selected the candidates for secondary cytoreductive surgery with iMODEL score of 4.7 or less even after the correction by PET-CT imaging. + Secondary cytoreductive surgery favorably impacts platinum-sensitive relapsed ovarian cancer, but incomplete resection leads to the worst survival compare to no-surgery. + Accumulating treatment-free survival, as an important secondary endpoint, was added to explore the long-term survival benefit affected by a high proportion of cross-over from the no surgery froup to the surgery group when overall survival data are mature. + In both primary and recurrent settings of ovarian cancer, randomized trials are needed to confirm the survival benefit of complete surgery followed by targeting maintenance therapy.